For the Inventor, By the Inventor

Enter assignee name

R-Tech Ueno, Ltd.

USPTO Granted Patents = 55

% Expired Patents = 21.8

CIPO Patents = 1

EPO Patents = 14

Forward Citations = 345

Loading Chart...

Loading Chart...

42 inventors (with patents filed for the assignee):

Ryuji Ueno (41 out of 151 patents)

Ryu Hirata (12 out of 13 patents)

Tatsuya Matsukawa (11 out of 14 patents)

4. Kazuhiro Masuzaki (7 out of 7 patents)

5. Yasuhiro Harada (7 out of 8 patents)

6. Ryuzo Ueno (6 out of 108 patents)

7. Tomio Oda (6 out of 32 patents)

8. Ichie Kato (4 out of 14 patents)

9. Akiko Kawasaki (3 out of 3 patents)

10. Akiko Akasaka (3 out of 3 patents)

11. Yosuke Kawai (3 out of 3 patents)

12. Yukiko Hashitera (3 out of 3 patents)

13. Yukihiko Mashima (3 out of 4 patents)

14. Junichi Kawasaki (2 out of 2 patents)

15. Yoshie Nishimura (2 out of 2 patents)

Core Competencies:

Prostaglandin Derivative

Ocular Hypertension

VAP-1 Inhibitor

Eye Drops

Soft-Gelatin Capsule

Hair Growth

Pharmaceutical Composition

Endothelin Antagonist

Albumin Composition

Cataract Treatment

Wound-Healing

Optic Nerve Disorder

55 patents: Sort by Forward Citations

1. 9603833 - Benzene or thiophene derivative and use thereof as VAP-1 inhibitor (2017-03-28),

2. 9254326 - Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound (2016-02-09),

3. 9254306 - Eye drops (2016-02-09),

4. 9242950 - Method for preparing a fatty acid derivative (2016-01-26),

5. 9212158 - Method for preparing a fatty acid derivative (2015-12-15),

6. 9205154 - Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method (2015-12-08),

7. 8999989 - Benzene or thiophene derivative and use thereof as VAP-1 inhibitor (2015-04-07),

8. 8969324 - Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound (2015-03-03),

9. 8871995 - Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and pharmaceutical composition obtained by the method (2014-10-28),

10. 8779187 - Soft-gelatin capsule formulation (2014-07-15),

11. 8686035 - Composition and method for promoting hair growth (2014-04-01),

12. 8669284 - Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound (2014-03-11),

13. 8507690 - Thiazole derivative and use thereof as VAP-1 inhibitor (2013-08-13),

14. 8389748 - Method for preparing prostaglandin derivative (2013-03-05),

15. 8338639 - Soft-gelatin capsule formulation (2012-12-25),

R-Tech Ueno, Ltd., headquartered in Osaka, Japan, specializes in the development and manufacturing of pharmaceutical compositions, with a strong focus on ocular health. The company is recognized for its innovative approaches to treating ocular hypertension through prostaglandin derivatives and VAP-1 inhibitors. Additionally, R-Tech Ueno is engaged in advancing therapeutic solutions for hair growth and other medical conditions, utilizing soft-gelatin capsules and endothelin antagonists to enhance patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

55 Patents

#177 in Osaka

#1,617 in Japan

#12,894 in the World

R-Tech Ueno, Ltd.

Forward Citations = 345

42 inventors:

Ryuji Ueno (41 out of 151 patents)

Ryu Hirata (12 out of 13 patents)

Tatsuya Matsukawa (11 out of 14 patents)

4. Kazuhiro Masuzaki (7 out of 7 patents)

5. Yasuhiro Harada (7 out of 8 patents)

Please report any incorrect information to [email protected]

Loading…